JP2017527578A5 - - Google Patents

Download PDF

Info

Publication number
JP2017527578A5
JP2017527578A5 JP2017513450A JP2017513450A JP2017527578A5 JP 2017527578 A5 JP2017527578 A5 JP 2017527578A5 JP 2017513450 A JP2017513450 A JP 2017513450A JP 2017513450 A JP2017513450 A JP 2017513450A JP 2017527578 A5 JP2017527578 A5 JP 2017527578A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
irritable bowel
bowel syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017513450A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017527578A (ja
JP6538154B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/056905 external-priority patent/WO2016038552A1/en
Publication of JP2017527578A publication Critical patent/JP2017527578A/ja
Publication of JP2017527578A5 publication Critical patent/JP2017527578A5/ja
Application granted granted Critical
Publication of JP6538154B2 publication Critical patent/JP6538154B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017513450A 2014-09-10 2015-09-09 Ret(rearranged during transfection)キナーゼ阻害剤としてのピリジン誘導体 Expired - Fee Related JP6538154B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2014086197 2014-09-10
CNPCT/CN2014/086197 2014-09-10
CNPCT/CN2015/086995 2015-08-14
CN2015086995 2015-08-14
PCT/IB2015/056905 WO2016038552A1 (en) 2014-09-10 2015-09-09 Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019102776A Division JP6728447B2 (ja) 2014-09-10 2019-05-31 Ret(rearranged during transfection)キナーゼ阻害剤としてのピリジン誘導体

Publications (3)

Publication Number Publication Date
JP2017527578A JP2017527578A (ja) 2017-09-21
JP2017527578A5 true JP2017527578A5 (enExample) 2018-10-25
JP6538154B2 JP6538154B2 (ja) 2019-07-03

Family

ID=54186249

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017513450A Expired - Fee Related JP6538154B2 (ja) 2014-09-10 2015-09-09 Ret(rearranged during transfection)キナーゼ阻害剤としてのピリジン誘導体
JP2019102776A Expired - Fee Related JP6728447B2 (ja) 2014-09-10 2019-05-31 Ret(rearranged during transfection)キナーゼ阻害剤としてのピリジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019102776A Expired - Fee Related JP6728447B2 (ja) 2014-09-10 2019-05-31 Ret(rearranged during transfection)キナーゼ阻害剤としてのピリジン誘導体

Country Status (36)

Country Link
US (4) US9918974B2 (enExample)
EP (2) EP3517526B1 (enExample)
JP (2) JP6538154B2 (enExample)
KR (1) KR20170045350A (enExample)
CN (1) CN107074768B (enExample)
AU (1) AU2015313841B2 (enExample)
BR (1) BR112017004900A2 (enExample)
CA (1) CA2960768A1 (enExample)
CL (1) CL2017000588A1 (enExample)
CO (1) CO2017002273A2 (enExample)
CR (1) CR20170093A (enExample)
CY (1) CY1121661T1 (enExample)
DK (1) DK3191450T3 (enExample)
DO (1) DOP2017000059A (enExample)
EA (1) EA033544B1 (enExample)
ES (2) ES2816453T3 (enExample)
HR (1) HRP20190815T1 (enExample)
HU (1) HUE044604T2 (enExample)
IL (1) IL250908B (enExample)
LT (1) LT3191450T (enExample)
MA (1) MA40581A (enExample)
ME (1) ME03432B (enExample)
MX (1) MX373863B (enExample)
MY (1) MY181913A (enExample)
PE (1) PE20170705A1 (enExample)
PH (1) PH12017500425B1 (enExample)
PL (1) PL3191450T3 (enExample)
PT (1) PT3191450T (enExample)
RS (1) RS58813B1 (enExample)
SG (1) SG11201701694QA (enExample)
SI (1) SI3191450T1 (enExample)
SM (1) SMT201900304T1 (enExample)
TW (1) TWI683807B (enExample)
UA (1) UA122213C2 (enExample)
UY (1) UY36293A (enExample)
WO (1) WO2016038552A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2918588T3 (pl) 2010-05-20 2017-10-31 Array Biopharma Inc Związki makrocykliczne jako inhibitory kinazy TRK
CA2960768A1 (en) 2014-09-10 2016-03-17 Glaxosmithkline Intellectual Property Development Limited Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
WO2016037578A1 (en) * 2014-09-10 2016-03-17 Glaxosmithkline Intellectual Property Development Limited Novel compounds as rearranged during transfection (ret) inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
WO2017011776A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
MX384884B (es) 2015-11-02 2025-03-14 Blueprint Medicines Corp Inhibidores de ret.
WO2017161269A1 (en) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibitors of ret receptor tyrosine kinases
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN110891573A (zh) 2017-05-15 2020-03-17 缆图药品公司 Ret抑制剂和mtorc1抑制剂的组合及其用于治疗由异常ret活性介导的癌症的用途
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
US11472802B2 (en) 2018-01-18 2022-10-18 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors
US11524963B2 (en) 2018-01-18 2022-12-13 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors
EP3773589B1 (en) 2018-04-03 2023-11-01 Blueprint Medicines Corporation Ret inhibitor for use in treating cancer having a ret alteration
EP3849986B1 (en) 2018-09-10 2022-06-08 Array Biopharma, Inc. Fused heterocyclic compounds as ret kinase inhibitors
KR20230017234A (ko) 2020-05-29 2023-02-03 블루프린트 메디신즈 코포레이션 프랄세티닙의 고체 형태
WO2022017524A1 (zh) * 2020-07-23 2022-01-27 深圳晶泰科技有限公司 吡啶酮类化合物及其制备方法和应用
WO2024043257A1 (ja) 2022-08-24 2024-02-29 東レ株式会社 癌の治療及び/又は予防のための医薬品

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
ES2153340T3 (es) 1997-12-22 2006-02-01 Bayer Pharmaceuticals Corp. Inhibicion de la quinasa raf utilizando ureas heterociclicas sustituidas.
ATE529109T1 (de) 1997-12-22 2011-11-15 Bayer Healthcare Llc Hemmung der p38 kinase aktivität durch substituierte heterocyclische harnstoffe
US20120046290A1 (en) 1997-12-22 2012-02-23 Jacques Dumas Inhibition of p38 kinase activity using substituted heterocyclic ureas
PL353455A1 (en) 1999-08-12 2003-11-17 Pharmacia Italia S.P.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
CA2430151A1 (en) 2000-11-27 2002-06-20 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
DE10201764A1 (de) 2002-01-18 2003-07-31 Bayer Cropscience Ag Substituierte 4-Aminopyridin-Derivate
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
AU2003264386A1 (en) 2002-09-10 2004-04-30 Kyorin Pharmaceutical Co., Ltd. 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
BRPI0413757A (pt) 2003-08-22 2006-10-31 Boehringer Ingelheim Pharma métodos para o tratamento de copd e da hipertensão pulmonar
TW200530236A (en) * 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
JP5124285B2 (ja) * 2004-12-28 2013-01-23 キネックス ファーマシューティカルズ, エルエルシー 細胞増殖性障害を処置する組成物および方法
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
GB0507575D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US8247556B2 (en) * 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
TW200804349A (en) * 2005-12-23 2008-01-16 Kalypsys Inc Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
DK2041071T3 (da) 2006-06-29 2014-09-01 Kinex Pharmaceuticals Llc Biarylsammensætninger og fremgangsmåder til modulering af en kinasekaskade
KR101507375B1 (ko) * 2006-09-15 2015-04-07 엑스커버리 홀딩 컴퍼니 엘엘씨 키나아제 억제제 화합물
RU2009118254A (ru) * 2006-10-16 2010-11-27 Новартис АГ (CH) Фенилацетамиды в качестве ингибиторов протеинкиназ
HUE035868T2 (en) 2006-11-15 2018-05-28 Ym Biosciences Australia Pty Inhibitors of kinase activity
JP2013502429A (ja) 2009-08-19 2013-01-24 アムビト ビオスシエンセス コルポラチオン ビアリール化合物及びその使用方法
WO2012082817A1 (en) 2010-12-16 2012-06-21 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
EP2970191B1 (en) * 2013-03-15 2016-12-21 GlaxoSmithKline Intellectual Property Development Limited Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors
US8937071B2 (en) 2013-03-15 2015-01-20 Glaxosmithkline Intellectual Property Development Limited Compounds as rearranged during transfection (RET) inhibitors
CA2960768A1 (en) * 2014-09-10 2016-03-17 Glaxosmithkline Intellectual Property Development Limited Pyridone derivatives as rearranged during transfection (ret) kinase inhibitors
WO2016037578A1 (en) 2014-09-10 2016-03-17 Glaxosmithkline Intellectual Property Development Limited Novel compounds as rearranged during transfection (ret) inhibitors

Similar Documents

Publication Publication Date Title
JP2017527578A5 (enExample)
JP2017526711A5 (enExample)
HRP20190815T1 (hr) Piridonski derivati korišteni kao inhibitori kinaze reorganizirane tijekom transfekcije (ret)
JP2013543896A5 (enExample)
JP2017528503A5 (enExample)
JP2013527202A5 (enExample)
JP2017504635A5 (enExample)
JP2017535550A5 (enExample)
JP2016503010A5 (enExample)
JP2015145426A5 (enExample)
NZ703941A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2014525470A5 (enExample)
JP2015516434A5 (enExample)
JP2015524472A5 (enExample)
JP2013526482A5 (enExample)
JP2017528507A5 (enExample)
NZ627750A (en) Carbamate compounds and of making and using same
JP2020510661A5 (enExample)
JP2009529541A5 (enExample)
JP2016516020A5 (enExample)
JP2021530565A5 (enExample)
JP2009541216A5 (enExample)
JP2014062126A5 (enExample)
JP2014502979A5 (enExample)
RU2014113679A (ru) N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1